Apollon Formularies - Issue of Equity
RNS Number : 3291P
Apollon Formularies plc
17 June 2022
 

17 June 2022

Apollon Formularies Plc

Issue of Equity

 

Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, announces the issue of shares as consideration for the acquisition of intellectual property from Aion Therapeutics Inc. (CSE: AION).

As announced on 5 May 2022, under the terms of the Commitment Agreement, Apollon has acquired the following patents and all associated supporting data including the pre-clinical testing results from BIOENSIS.

1.    Compositions and Methods for Treatment of Cancers.

2.    Compositions and Methods for Treatment of Inflammation.

3.    Methods for Treatment of Human Cancers using Mushroom Compositions.

4.    Methods for Treatment of Human Cancers using Cannabis Compositions.

The Company has therefore allotted 4,348,679 new Ordinary Shares of the Company. These Ordinary Shares will be subject to a complete trading restriction for a period of six (6) calendar months from the date of the stock transfer. After the six (6) month restriction period, twenty percent (20%) of such stock received will become eligible for trading, and an additional twenty percent (20%) will be tradable at the end of each following three-month period, with all trading restrictions being fully removed at the end of eighteen (18) months.

Application will be made for the new Ordinary Shares to be admitted to trading on the AQSE Growth Market and admission is expected to become effective, and dealings in the new Ordinary Shares are expected to commence, on 26 June 2022.

Following this issue, the Company has 752,725,356 Ordinary Shares in issue, each share carrying the right to one vote. The figure of 752,725,356 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The Directors of the Company accept responsibility for the contents of this announcement.

 

ENDS

For additional information, please visit www.apollon.org.uk or contact:

 

Apollon Formularies                                                     

Tel:                                                         +44 771 198 0221

Stene Jacobs                                      stene@apollon.org.uk

 

Peterhouse Capital Limited (Corporate Adviser)             

Tel:                                                         +44 207 220 9795

Guy Miller                                           gm@peterhousecapital.com

 

BlytheRay (Financial PR/IR-London)      

Tel:                                                         +44 207 138 3204

Tim Blythe/Megan Ray                  apollon@blytheray.com

 

About Apollon and Apollon Jamaica

Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision. Apollon and Apollon Jamaica are parties to a Commitment Agreement whereby Apollon is entitled to 95% of Apollon Jamaica's Net Profits, and per a Stock Pledge Agreement that includes Stephen D. Barnhill, M.D., Apollon is to be assigned the entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill, which is the maximum interest in a medical cannabis company allowed to be held by a non-Jamaican, upon the CLA approving the assignment.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXBDGDLDDBDGDR ]]>